Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
A Process and Enterprise Maturity Model (PEMM) Analysis of the Hampered Big Pharma Drug Discovery Process
Blekinge Institute of Technology, Faculty of Engineering, Department of Industrial Economics.
Blekinge Institute of Technology, Faculty of Engineering, Department of Industrial Economics.
2017 (English)Independent thesis Advanced level (degree of Master (One Year)), 10 credits / 15 HE creditsStudent thesis
Abstract [en]

The big pharma drug discovery process is currently hampered by long lead times, high costs, and fre-quent failures. On the other hand the general view is that many small pharmaceutical and biotech com-panies are more successful in terms of preclinical drug project transitions, and many small companies and/or their projects are bought by big pharma.

In this thesis we investigated if the Business Process Reengineering (BPR) and the Process and Enterprise Maturity Model (PEMM) approaches by Hammer are suitable for the big pharma R&D process and if these approaches could shed any light on where potential improvements in the process can be made. A number of people with work experience from both big pharma and biotech preclinical R&D were also interviewed regarding the BPR and PEMM approaches and also regarding general organizational and pro-cess differences between biotech and big pharma.

Our findings suggests that where suitable, most of the BPR principles have already been implemented in big pharma R&D, and that the PEMM approach at large, is suitable for the industry. Further, the inter-views revealed that there is a stronger focus on the core science and project work, and much less focus on processes, in biotech compared to big pharma. Despite a higher focus on control in terms of pro-cesses and metrics, the big pharma R&D process suffers, indicating a need to strengthen the process cul-ture if these processes should remain and add value to the organization.

Place, publisher, year, edition, pages
2017.
National Category
Business Administration
Identifiers
URN: urn:nbn:se:bth-15368OAI: oai:DiVA.org:bth-15368DiVA: diva2:1151205
Subject / course
IY2578 Master's Thesis (60 credits) MBA
Educational program
IYABA MBA programme
Supervisors
Examiners
Available from: 2017-10-30 Created: 2017-10-23 Last updated: 2017-10-30Bibliographically approved

Open Access in DiVA

fulltext(966 kB)8 downloads
File information
File name FULLTEXT02.pdfFile size 966 kBChecksum SHA-512
6bf5fab7a47fa19a266e5594c7eeba8e167998405094710d9b8b4059c5c3e169615b8abec0e56ad8dc7bcd14e3ad355785d00441783c9a3c0c1fa7316d3b0c28
Type fulltextMimetype application/pdf

By organisation
Department of Industrial Economics
Business Administration

Search outside of DiVA

GoogleGoogle Scholar
Total: 8 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Total: 18 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf